MEDIA STORIES
26-Aug-2024
Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw
25-June-2024
EMA approves Biocon Biologics’ new monoclonal antibodies facility, renews GMP certifications for India and Malaysia sites
24-June-2024
Biocon Biologics gets EMA nod to manufacture biosimilar Bevacizumab at its new facility in Bengaluru
24-June-2024
Aim is to be among top three biosimilars players globally: Biocon Biologics CEO Shreehas Tambe
27-May-2024
Acceleration of biosimilar business, debt reduction to be key priorities in FY25: Biocon Chief
18-May-2024
Biocon’s Biosimilar Business Set For Strong Growth: CEO Shreehas Tambe
18-May-2024
Biocon Biologics Signs 10-Year Deal With Eris Lifesciences To Expand Patient Access
14-Mar-2024
Biocon Biologics: US Biosimilars Are A Marathon, Not A Sprint
13-Mar-2024
Biocon Biologics Secures US Entry Date For Bmab 1200, A Stelara Biosimilar
01-Mar-2024
Biocon included in S&P Global Sustainability Yearbook 2024
20-Feb-2024
Biocon Biologics focusing on market share gains of biosimilars in key markets
13-Feb-2024
We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics
12-Feb-2024
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia
09-Feb-2024
Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw
02-Feb-2024
Biocon to commercialize biosimilars in 31 European countries
22-Dec-2023
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
22-Dec-2023
Biocon Biologics completes integration of Viatris’ biosimilars business
18-Dec-2023
Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition
15-Dec-2023
Taking Control Of Our Destiny: Biocon Biologics CEO Tambe Celebrates European Viatris Integration
07-Dec-2023
Biocon Biologics integrates Viatris’ biosimilar biz in 31 European nations
30-Nov-2023
Interview With Shreehas Tambe, MD On Biocon’s Strong Q2 Earnings And Acquisition Plans
15-Nov-2023
Biocon Biologics targets top three biosimilar spot: Shreehas Tambe
13-Nov-2023
Biocon Biologics receives UK regulator’s approval for ophthalmic drug YESAFILI
13-Nov-2023
Biocon Biologics to sell 2 non-core branded formulations businesses to Eris Lifesciences for ₹366 cr
08-Nov-2023
Kedar Upadhye steps in as new CFO of Biocon Biologics
19-Oct-2023
Biocon Biologics integrates Viatris Biosimilars in North America, shares up
07-Sep-2023
Biocon Biologics announces top leadership appointments
04-Aug-2023
Biocon Biologics completes integration of biosimilars business in 70+ emerging markets
05-July-2023
Biocon Biologics Ltd launches biosimilar HULIO in US
05-July-2023
Biocon Biologics Ltd launches biosimilar HULIO in US
05-July-2023
Biocon Biologics Receives EU Good Manufacturing Practice Certification
10-July-2022
Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate
06-July-2022
Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru
05-July-2022
Biocon Biologics expects big gains from integration of Viatris business, SII deal
09-June-2022
Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics
04-May-2022
Biocon Biologics may close $3.34 billion Viatris deal in Q1
02-May-2022
Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe
30-April-2022
Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year
29-April-2022
Biocon Biologics acquires Viatris for $3.33 billion
01-Mar-2022
Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal
28-Feb-2022
R&D expenditure will rise in the coming quarters: Biocon Biologics MD
25-Jan-2022
Insulins access program for young expanded in Dec quarter: Biocon Biologics MD
24-Jan-2022
Biocon Biologics set to reap biosimilar insulin glargine opportunity in US
22-Jan-2022
The Medicine Box: Kiran Mazumdar-Shaw on biosimilar interchangeable status for Biocon’s diabetes drug
25-Nov-2021
Biocon Biologics, Viatris confirm offering steep savings on long-acting insulin through Walgreens Prescription Savings Club
19-Nov-2021
Walgreens to sell Biocon’s insulin Semglee in the U.S.
19-Nov-2021
Biocon Biologics, Viatris launch interchangeable insulin biosimilar for US
16-Nov-2021
Biocon Rating: Hold – Vaccines to complement biosimilar portfolio
20-Sep-2021
Biocon Biologics, Serum Institute Life Sciences announce strategic alliance
20-Sep-2021
Interchangeable insulin to help us compete with big insulin makers: Kiran Mazumdar-Shaw
29-Aug-2021
Shreehas Tambe named Deputy CEO of Biocon Biologics
02-Mar-2021
Biocon Biologics, Viatris get CHMP nod for Abevmy
02-Mar-2021
Biocon Biologics to partner with International Diabetes Federation
16-Feb-2021
Biocon Biologics Receives USD 150 Million Capital Injection from Goldman Sachs
08-Nov-2020
India-based company brings affordable insulin to 2 PH towns
23-Oct-2020
India’s Biocon secures approval to use drug on coronavirus patients
11-July-2020
Biosimilar drugs can help us reach $1 billion target soon
16-Jun-2020
Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020
06-Jun-2020
Covid provides larger opportunity to shape the biosimilar landscape
19-May-2020
Biocon’s cancer biosimilar gets US FDA acceptance for review
10-Mar-2020
Biocon chief is EY entrepreneur for 2019
22-Feb-2020
Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw
27-Jan-2020
Biocon, partner Mylan launch oncology biosimilar trastuzumab in US
11-Dec-2019
Biocon, Mylan get nod for pegfilgrastim drug
28-Nov-2019
Indian company makes it to top 10 best employers in biotech category
30-Oct-2019
Insulin at ₹7 will be a gamechanger for us
26-Oct-2019
Life-enabling product like insulin should be made affordable: Shaw
28-Sep-2019
Biocon plans to halve insulin prices
27-Sep-2019
Biocon sets $1 billion target for biologics business
25-Oct-2019
Biocon subsidiary acquires Pfizer’s R&D facility in Chennai
25-Sep-2019
Ramp-up of biosimilar portfolio to boost Biocon
22-Aug-2019
Our aim is to be a global leader in biosimilars biz: Biocon Biologics CEO
30-Jul-2019
Biosimilars, research key drivers for Biocon
18-Jun-2019
Trastuzumab’s US launch will be a big opportunity for Biocon-Mylan: Shaw
18-Jun-2019
Biocon’s Bengaluru biologics units get European agency nod
15-Jun-2019
The First Lady of Biotech
08-Jun-2019
Canada clears Mylan & Biocon’s Biosimilar
23-May-2019
Biocon drug gets commercial rights to global markets
09-May-2019
Biosimilars to help Biocon hit $1bn revenue in FY20
30-Apr-2019
Kiran Mazumdar-Shaw conferred with honorary doctorate from Deakin University, Australia
18-Apr-2019
Research must be promoted in colleges
08-Apr-2019
ET Prime celebrates Women’s Excellence in Business & Innovation
05-Apr-2019
Breakthrough innovation is taking place but we’re not leveraging it
05-Apr-2019
Kiran Mazumdar-Shaw conferred with Honorary Doctorate
04-Apr-2019
Biocon Biologics India appoints Dr. Christiane Hamacher as CEO
01-Apr-2019
Biocon chief stresses on gender equality
29-Mar-2019
Kiran back as Infy’s independent director
19-Mar-2019
Govt Should Scale Up Philanthropic Capital
18-Mar-2019
Cost of select insulin increases up to 20%
15-Mar-2019
Role of Indian women in Science & Technology
12-Mar-2019
The growing share of biosimilars revenue is doing wonders for our business
11-Mar-2019
Biosimilars offer a huge opportunity for Biocon
08-Mar-2019
Future jobs will be different: Shaw
07-Mar-2019
Pharma specialist new CEO of Biocon Biologics
03-Mar-2019
Hamacher is CEO of Biocon Biologics
02-Mar-2019
In bid to curb profiteering, govt caps margins of 42 cancer drugs
28-Feb-2019
Shortage of women for leadership roles
23-Feb-2019
Biocon’s Trastuzumab receives approvals in EU
13-Feb-2019
Kiran Mazumdar-Shaw elected member of US-based NAE
09-Feb-2019
Biosimilars make Biocon stand apart
28-Jan-2019
